About Nora Therapeutics
Nora Therapeutics is a Healthcare company based in Palo Alto (United States) founded in 2007. It operates as a therapeutics for IVF failure and recurrent pregnancy loss are developed. Nora Therapeutics has raised $37.81 million across 5 funding rounds from investors including Burrill and Company, Prospect Venture Partners and Rho Capital Partners. Its focus areas include Life Sciences, Women Health, Drugs and Reproductive Diseases. Its competitors include Sprout Pharmaceuticals, ObsEva, Hope Medicine, Rejoni and Gameto and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
Developer of therapeutics to address IVF failure and recurrent pregnancy loss. Its product includes NT100 (a proprietary recombinant form of human granulocyte colony-stimulating factor (G-CSF), a biologic agent similar to a naturally occurring protein in the female reproductive tract that may reduce the risk of miscarriage by optimizing maternal-fetal immune tolerance in women who have a history of unexplained recurrent miscarriage.
- Headquarters Palo Alto, United States
- SectorsHealthcare
- Phone•••• ••••
- Website noratherapeutics.com
- Social LinkedIn
- Total Equity Funding$37.81M (USD)
in 5 rounds
- Latest Funding Round$1M (USD), Series B
Oct 2015
- InvestorsBurrill and Company
& 4 more
Funding Insights of Nora Therapeutics
Nora Therapeutics has successfully raised a total of $37.81M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $1 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.81M
- Total Rounds 5
- Last Round Series B — $1M
- First Round $1M
(Apr 2009)
- Investors Count 5
All 5 funding rounds of Nora Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $1M | Series B | – | – | – |
| Apr 2014 | $18M | Series B | – | Novo Holdings | |
| Sep 2010 | $14.88M | Series A | – | – | – |
| Jun 2010 | $2.93M | Series A | – | – | – |
| Apr 2009 | $1M | Seed | – | – | – |
5 investors in total: 5 institutional.
Investors in Nora Therapeutics
Nora Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Burrill and Company, Prospect Venture Partners and Rho Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in US life sciences and healthtech firms. | – | prospectventures.com | Palo Alto, United States | |
Early-stage tech startups are invested in by Rho Capital Partners. | – | rho.com | New York, United States | |
Venture capital and private equity firm | – | vivocapital.com | Palo Alto, United States | |
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China |
Investor details for Nora Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Nora Therapeutics
3 dated milestones of Nora Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Nora Therapeutics is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series B, of $1.0M.
Competitors of Nora Therapeutics
Nora Therapeutics has 8 listed competitors in our database, 8 of them funded. They include Sprout Pharmaceuticals, ObsEva, Hope Medicine, Rejoni and Gameto, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sproutpharmaceuticals.com | 2011 | Raleigh, United States | $185.16M | 31 | Drugs for hypoactive sexual desire disorder in women are developed. | |
| obseva.com | 2012 | Geneva, Switzerland | $94.7M | – | Therapeutics for women's reproductive health and pregnancy are developed. | |
| hopemedinc.com | 2018 | Shanghai, China | $56M | – | Monoclonal antibodies are developed for treating multiple diseases. | |
| rejoni.com | 2020 | Bedford, United States | $41.25M | – | Therapeutics for women's health conditions are developed using innovative hydrogels. | |
| gametogen.com | 2020 | United States | $127M | – | Therapeutics for fertility and menopause treatments are developed. | |
| naari.co | 2007 | Noida, India | $18.98M | 195 | Women care medicines are manufactured by Naari in India. | |
| forendo.com | 2013 | Turku, Finland | $25.58M | – | Small molecule therapeutics for reproductive health are developed. | |
| preglem.com | 2006 | Geneva, Switzerland | $57.94M | – | Innovative drugs for women's reproductive medicine are developed and commercialized. |
Detailed competitors of Nora Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Women's Health & Fertility
10 companies that operate in the same segment as Nora Therapeutics (Women's Health & Fertility), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Internet first brand offering wearable breast pumps | 2013 | London, England, United Kingdom | USD 157.63 M | – | – | |
Silicone-filled breast and body shaping implants are designed and manufactured. | 2010 | Alajuela, Alajuela, Costa Rica | USD 121 M | USD 211.08 M | 1,020 | |
Immunotherapeutics for cancer and other diseases are developed. | 2008 | Mainz, Rhineland-palatinate, Germany | USD 805.99 M | USD 3.24 B | 6,770 | |
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | – | |
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | – | 861 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Platform for breast ultrasound imaging | 2010 | Plymouth, Massachusetts, United States | USD 136.54 M | – | – | |
Silicone breast implants are developed for reconstruction and aesthetic surgery. | 2007 | Dublin, Ireland | USD 232.81 M | – | – | |
A minimally invasive ablation system for uterine fibroids is developed. | 2005 | Redwood City, California, United States | USD 282.54 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nora Therapeutics
Complete news archive for Nora Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nora Therapeutics
Nora Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Nora Therapeutics is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Nora Therapeutics is a funded company, having raised a total of $37.81M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Apr 2009.
Developer of therapeutics to address IVF failure and recurrent pregnancy loss. Its product includes NT100 (a proprietary recombinant form of human granulocyte colony-stimulating factor (G-CSF), a biologic agent similar to a naturally occurring protein in the female reproductive tract that may reduce the risk of miscarriage by optimizing maternal-fetal immune tolerance in women who have a history of unexplained recurrent miscarriage.
Nora Therapeutics's top competitors include Sprout Pharmaceuticals, Rejoni and Hope Medicine.
Nora Therapeutics has 5 investors. Key investors include Burrill and Company, Prospect Venture Partners, Rho Capital Partners, Vivo Capital, and Novo Holdings.